Biocon Ltd. — Capital/Financing Update 2024

Oct 9, 2024

==> picture [132 x 52] intentionally omitted <==

Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T: 91 80 2808 2808 F: 91 80 2852 3423

CIN: L24234KA1978PLC003417

www.biocon.com

BIO/SECL/SP/2024-25/108

October 09, 2024

To,The ManagerBSE LimitedDepartment of Corporate ServicesPhiroze Jeejeebhoy Towers,Dalal Street,Mumbai – 400 001	To,The ManagerBSE LimitedDepartment of Corporate ServicesPhiroze Jeejeebhoy Towers,Dalal Street,Mumbai – 400 001	To,The ManagerBSE LimitedDepartment of Corporate ServicesPhiroze Jeejeebhoy Towers,Dalal Street,Mumbai – 400 001	To,The ManagerBSE LimitedDepartment of Corporate ServicesPhiroze Jeejeebhoy Towers,Dalal Street,Mumbai – 400 001	To,The ManagerNational Stock Exchange of India LimitedCorporate Communication DepartmentExchange Plaza, Bandra Kurla ComplexMumbai – 400 050	To,The ManagerNational Stock Exchange of India LimitedCorporate Communication DepartmentExchange Plaza, Bandra Kurla ComplexMumbai – 400 050
Sc	rip Code – 532523			Scrip Symbol – Biocon
	ar Sir/Madam,

Dear Sir/Madam,

Subject: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

This is further to our letters dated September 24, 2024 and October 03, 2024, we are pleased to inform you that Biocon Biologics Global Plc (the “Issuer”), incorporated under the laws of the United Kingdom and being a subsidiary of Biocon Biologics UK Limited, which is a subsidiary of Biocon Biologics Limited (“Biocon Biologics”) and a step-down subsidiary of the Biocon Limited (the “Company”), has raised US $ 800 million by allotment of US dollar denominated senior secured notes (the “Notes”).

The Notes shall be listed on the Singapore Exchange Securities Trading Limited (“SGX-ST”) and were not offered or sold in India.

Further, pursuant to an Indenture dated October 09, 2024, the Notes have been irrevocably and unconditionally guaranteed by, among others, Biocon Biologics, a material subsidiary of the Company (the “Guarantee”), and secured by, among others, a pledge over certain shares held by Biocon Biologics in Biosimilars Newco. Limited, being a subsidiary of Biocon Biologics.

Please find below certain key details of the Notes:

Particulars	Terms
Notes Offered	US$800 million of 6.67% Senior Secured Notes due 2029
Tenure	5years
Issue Price	99.041%
MaturityDate	October 09,2029.
Interest	6.67% per annum, payable semi-annually in arrears on each April 09 and October 09,commencingon April 09,2025.
Listing	SGX-ST

==> picture [132 x 52] intentionally omitted <==

The above information will also be available on the website of the Company at www.biocon.com.

Kindly take the above information on record and acknowledge.

Thanking You,

Yours faithfully,

For Biocon Limited

MAYANK Digitally signed by MAYANK VERMA VERMA Date: 2024.10.09 21:24:37 +05'30'

---

Mayank Verma Company Secretary & Compliance Officer Membership No.: ACS 18776

==> picture [132 x 52] intentionally omitted <==

Disclaimer:

The Notes were not offered or sold in India, including by means of any document or any other offering document or material relating to the Notes, directly or indirectly, to any person or to the public in India or any offshore branch or a subsidiary of an Indian bank which would constitute an advertisement, invitation, offer, sale or solicitation of an offer to subscribe for or purchase any securities in violation of applicable Indian laws. The Notes were offered or sold (i) within the United States to persons reasonably believed to be qualified institutional buyers (“ QIBs ”) in accordance with Rule 144A under the Securities Act of 1933, as amended (the “ Securities Act ”) and (ii) outside the United States in “offshore transactions” as defined in, and in reliance on Regulation S under the Securities Act.

This intimation is for information purposes only and is not a prospectus, disclosure document or other offering document under any law, nor does it form part of, and should not be construed as, any present or future invitation, recommendation or offer to purchase or sell securities of the Company, the Issuer or Biocon Biologics or an inducement to enter into investment activity in any jurisdiction. No part of this intimation nor the fact of its distribution should form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever. Any decision to purchase the Notes should be made solely on the basis of information contained in the Offering Memorandum published in relation to such offering.

This information is not an offer of securities for sale in the United States or any other jurisdiction where it is unlawful to do so. The securities referred to herein have not been and will not be registered under the Securities Act or any securities laws of any state of the United States or and the securities may not be offered or sold in the United States or in any other jurisdiction. Nothing in this communication shall constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction in which such offer or sale would be unlawful.

The Offering Memorandum for the Notes has not been, nor will it be, registered, produced or published as an offer document (whether a prospectus in respect of a public offer, a statement in lieu of a prospectus or information memorandum, private placement offer cum application letter, an offering circular, an offering memorandum or other offering materials in respect of any private placement under the Companies Act, 2013, as amended, regulations formulated by Securities and Exchange Board of India or any other applicable Indian laws) with any Registrar of Companies, the Securities and Exchange Board of India (“ SEBI ”), the Reserve Bank of India or any Indian stock exchange or any other statutory or regulatory body of like nature in India, save and except for any information which is mandatorily required to be disclosed or filed in India under any applicable Indian laws (including, but not limited to, the SEBI (Prohibition of Insider Trading) Regulations 2015, as amended, and under the listing agreement with any Indian stock exchange pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended) or pursuant to the sanction of any regulatory and adjudicatory body in India. The securities mentioned herein will not be offered or sold, and have not been offered or sold, to any person resident in India by means of any document or otherwise, whether as a principal or agent. The securities mentioned herein have not been offered or sold, and will not be offered or sold to any person, in India in circumstances which would constitute an advertisement, invitation, offer, sale or solicitation of an offer to subscribe for or purchase any securities (whether to the public or by way of private placement) within the meaning of the Companies Act, 2013 or any other applicable Indian laws for the time being in force.